文献速递肝病消化道肿瘤与早癌

纳米脂质体C6-神经酰胺增强抗肿瘤免疫反应并减缓小鼠肝脏肿瘤生长

Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice.
PubMed 文献 · Gastroenterology · 2018-01-31

研究在小鼠肝细胞癌模型中,尾静脉注射载C6-神经酰胺纳米脂质体(LipC6)可减少肿瘤相关巨噬细胞数量及其活性氧产生,诱导M1表型,并增强肿瘤抗原特异性CD8+ T细胞的抗肿瘤效果,从而减缓肿瘤生长。

要点

  • LipC6注射可减少肿瘤相关巨噬细胞数量及其活性氧产生。
  • LipC6诱导肿瘤相关巨噬细胞向M1表型分化,降低免疫抑制。
  • LipC6联合肿瘤抗原特异性CD8+ T细胞及免疫接种使肿瘤生长更慢。

核心结论

  • 在有肝脏肿瘤的小鼠中,注射LipC6减少肿瘤相关巨噬细胞数量及其抑制抗肿瘤免疫反应的能力。
  • LipC6还增强肿瘤抗原特异性CD8+ T细胞的抗肿瘤效果。
  • LipC6可能因此提高肝细胞癌患者免疫治疗的疗效。

研究设计与样本

  • 研究使用免疫健全C57BL/6小鼠,经腹腔注射四氯化碳并经脾内注射致癌性肝细胞,在纤维化肝脏背景下形成类似人肝细胞癌的肿瘤。
  • 肿瘤形成后,每隔一天经尾静脉注射LipC6或载体,持续2周;随后经尾静脉给予从line 416小鼠脾脏分离的肿瘤抗原特异性CD8+ T细胞,并经腹腔注射表达肿瘤抗原的B6/WT-19细胞进行免疫。
  • 用磁共振成像监测肿瘤生长,用免疫组化和免疫印迹分析肿瘤凋亡、增殖和AKT表达,用流式细胞术、实时PCR和ELISA研究细胞因子产生、表型及功能。

主要发现

  • 与载体相比,注射LipC6通过减少肿瘤细胞增殖和AKT磷酸化、增加肿瘤细胞凋亡来减缓肿瘤生长。
  • 与单用载体、LipC6、T细胞或免疫接种的小鼠相比,接受LipC6注射联合肿瘤抗原特异性CD8+ T细胞随后免疫接种的小鼠肿瘤生长更慢。
  • LipC6注射减少肿瘤相关巨噬细胞数量及其活性氧产生,并诱导肿瘤相关巨噬细胞向M1表型分化,从而减少免疫抑制并增加CD8+ T细胞活性。
  • 用集落刺激因子2(GMCSF或CSF2)或集落刺激因子1(MCSF或CSF1)诱导的骨髓来源巨噬细胞实验验证了上述结果。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Ceramide, a sphingolipid metabolite, affects T-cell signaling, induces apoptosis of cancer cells, and slows tumor growth in mice. However, it has not been used as a chemotherapeutic agent because of its cell impermeability and precipitation in aqueous solution. We developed a nanoliposome-loaded C6-ceremide (LipC6) to overcome this limitation and investigated its effects in mice with liver tumors. METHODS: Immune competent C57BL/6 mice received intraperitoneal injections of carbon tetrachloride and intra-splenic injections of oncogenic hepatocytes. As a result, tumors resembling human hepatocellular carcinomas developed in a fibrotic liver setting. After tumors formed, mice were given an injection of LipC6 or vehicle via tail vein every other day for 2 weeks. This was followed by administration, also via tail vein, of tumor antigen-specific (TAS) CD8+ T cells isolated from the spleens of line 416 mice, and subsequent immunization by intraperitoneal injection of tumor antigen-expressing B6/WT-19 cells. Tumor growth was monitored with magnetic resonance imaging. Tumor apoptosis, proliferation, and AKT expression were analyzed using immunohistochemistry and immunoblots. Cytokine production, phenotype, and function of TAS CD8+ T cells and tumor-associated macrophages (TAMs) were studied with flow cytometry, real-time polymerase chain reaction (PCR), and ELISA. Reactive oxygen species (ROS) in TAMs and bone marrow-derived macrophages, induced by colony stimulating factor 2 (GMCSF or CSF2) or colony stimulating factor 1 (MCSF or CSF1), were detected using a luminescent assay. RESULTS: Injection of LipC6 slowed tumor growth by reducing tumor cell proliferation and phosphorylation of AKT, and increasing tumor cell apoptosis, compared with vehicle. Tumors grew more slowly in mice given the combination of LipC6 injection and TAS CD8+ T cells followed by immunization compared with mice given vehicle, LipC6, the T cells, or immunization alone. LipC6 injection also reduced numbers of TAMs and their production of ROS. LipC6 induced TAMs to differentiate into an M1 phenotype, which reduced immune suppression and increased activity of CD8+ T cells. These results were validated by experiments with bone marrow-derived macrophages induced by GMCSF or MCSF. CONCLUSIONS: In mice with liver tumors, injection of LipC6 reduces the number of TAMs and the ability of TAMs to suppress the anti-tumor immune response. LipC6 also increases the anti-tumor effects of TAS CD8+ T cells. LipC6 might therefore increase the efficacy of immune therapy in patients with hepatocellular carcinoma.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Li G, Liu D, Kimchi ET, et al. Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice. Gastroenterology. 2018. PMID: 29408569. doi:10.1053/j.gastro.2017.10.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。